Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.
about
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancerOvercoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies.The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer
P2860
Q33749044-0F3CAA7F-9EF7-439A-AA05-FBDD3F28DBA1Q38682200-C412146D-3A5F-4560-991F-E164E1C26FB6Q39282981-F193A919-169E-41EA-970C-9F8A80FF369EQ47629735-2931DD87-6C8F-440C-8814-412E17B4BD42Q49718838-2DBBC681-6645-4F42-8E2A-8200FBEBD98EQ52724347-B8B37AC5-10EA-4869-B9BD-BC34DB298BF2Q57164771-180EC5A8-E69B-4496-8C6E-1D3DDF87AFF9
P2860
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Fifth Ovarian Cancer Consensus ...... InterGroup: recurrent disease.
@en
Fifth Ovarian Cancer Consensus ...... InterGroup: recurrent disease.
@nl
type
label
Fifth Ovarian Cancer Consensus ...... InterGroup: recurrent disease.
@en
Fifth Ovarian Cancer Consensus ...... InterGroup: recurrent disease.
@nl
prefLabel
Fifth Ovarian Cancer Consensus ...... InterGroup: recurrent disease.
@en
Fifth Ovarian Cancer Consensus ...... InterGroup: recurrent disease.
@nl
P2093
P356
P1433
P1476
Fifth Ovarian Cancer Consensus ...... InterGroup: recurrent disease
@en
P2093
A M Ferrero
D Gallardo-Rincon
E Pujade-Lauraine
P304
P356
10.1093/ANNONC/MDW663
P577
2017-04-01T00:00:00Z